TipRanks
Advertisement
Advertisement

CHRS Stock Latest News

Coherus Biosciences Launches $50 Million ATM Equity Program
Company AnnouncementsCoherus Biosciences Launches $50 Million ATM Equity Program
21d ago
8K
CHRS
Coherus Earnings Call: Oncology Focus, Cash Trade‑Offs
PremiumCompany Announcements
Coherus Earnings Call: Oncology Focus, Cash Trade‑Offs
1M ago
CHRS
Coherus Biosciences Secures New Term Loan, Refinances Debt
PremiumCompany Announcements
Coherus Biosciences Secures New Term Loan, Refinances Debt
1M ago
8K
CHRS
Coherus Biosciences Issues Contingent Value Rights Dividend
PremiumCompany Announcements
Coherus Biosciences Issues Contingent Value Rights Dividend
1M ago
8K
CHRS
Coherus Oncology issuing special dividend of biosimilar contingent value rights
PremiumThe Fly
Coherus Oncology issuing special dividend of biosimilar contingent value rights
1M ago
CHRS
Coherus Oncology price target lowered to $10 from $12 at Guggenheim
PremiumThe FlyCoherus Oncology price target lowered to $10 from $12 at Guggenheim
1M ago
CHRS
Buy Rating Reiterated on Loqtorzi Rebound, Pipeline Catalysts, and Unchanged $7 Price Target
Premium
Ratings
Buy Rating Reiterated on Loqtorzi Rebound, Pipeline Catalysts, and Unchanged $7 Price Target
1M ago
CHRS
Coherus Oncology reports Q2 EPS (19c), consensus (12c)
Premium
The Fly
Coherus Oncology reports Q2 EPS (19c), consensus (12c)
1M ago
CHRS
Coherus Biosciences (CHRS) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Coherus Biosciences (CHRS) Q2 Earnings Cheat Sheet
2M ago
CHRS
Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study
PremiumThe Fly
Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study
3M ago
CHRS
Coherus Biosciences Announces 2026 Stockholder Meeting Results
PremiumCompany Announcements
Coherus Biosciences Announces 2026 Stockholder Meeting Results
4M ago
8K
CHRS
Coherus Biosciences Signals Momentum in Earnings Call
PremiumCompany Announcements
Coherus Biosciences Signals Momentum in Earnings Call
4M ago
CHRS
Coherus Biosciences Signals Confident Oncology Earnings Outlook
PremiumCompany AnnouncementsCoherus Biosciences Signals Confident Oncology Earnings Outlook
4M ago
CHRS
Analyst Reiterates Buy on Loqtorzi Momentum and Temporary Q1 Headwinds; $7 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Loqtorzi Momentum and Temporary Q1 Headwinds; $7 Price Target Maintained
4M ago
CHRS
Coherus Oncology reports Q1 EPS (28c), consensus (26c)
Premium
The Fly
Coherus Oncology reports Q1 EPS (28c), consensus (26c)
4M ago
CHRS
Guggenheim starts Coherus with Buy on anti-tumor potential
PremiumThe Fly
Guggenheim starts Coherus with Buy on anti-tumor potential
4M ago
CHRS
Coherus Oncology initiated with a Buy at Guggenheim
PremiumThe Fly
Coherus Oncology initiated with a Buy at Guggenheim
4M ago
CHRS
CHRS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CHRS Earnings this Week: How Will it Perform?
5M ago
CHRS
Coherus BioSciences Charts Leaner Path After Earnings Call
PremiumCompany Announcements
Coherus BioSciences Charts Leaner Path After Earnings Call
6M ago
CHRS
Coherus BioSciences: Buy Rating Backed by LOQTORZI’s Market Leadership and Advancing Immuno-Oncology Pipeline
PremiumRatingsCoherus BioSciences: Buy Rating Backed by LOQTORZI’s Market Leadership and Advancing Immuno-Oncology Pipeline
6M ago
CHRS
Coherus: Strategic Oncology Pivot and Loqtorzi Growth Drive Buy Rating
Premium
Ratings
Coherus: Strategic Oncology Pivot and Loqtorzi Growth Drive Buy Rating
6M ago
CHRS
Coherus Oncology reports Q4 EPS (34c), consensus (31c)
Premium
The Fly
Coherus Oncology reports Q4 EPS (34c), consensus (31c)
6M ago
CHRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >